TNXP
Tonix Pharmaceuticals Holding Corp
NASDAQ: TNXP · HEALTHCARE · BIOTECHNOLOGY
$12.93
+4.27% today
Updated 2026-04-30
Market cap
$179.13M
P/E ratio
—
P/S ratio
13.67x
EPS (TTM)
$-14.57
Dividend yield
—
52W range
$12 – $70
Volume
0.4M
WallStSmart proprietary scores
34
out of 100
Grade: F
Strong Sell
Investment rating
7.3
Growth
B+7.5
Quality
B+2.5
Profitability
F5.0
Valuation
C+6/9
Piotroski F-Score
Moderate
-4.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$54.33
+320.19%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Revenue growth 108.80% QoQ
+ Debt/equity 0.00x — low leverage
Risks
- Altman Z -4.42 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-41.52M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $9.03M | $7.77M | $10.09M | $13.11M | $13.11M |
| Net income | $-115.00M | $-116.66M | $-130.04M | $-124.02M | $-46.91M |
| EPS | — | — | — | — | $-14.57 |
| Free cash flow | $-146.20M | $-109.90M | $-61.05M | $-103.21M | $-41.52M |
| Profit margin | -1,274.00% | -1,501.78% | -1,288.25% | -946.22% | — |
Peer comparison
Smart narrative
Tonix Pharmaceuticals Holding Corp trades at $12.93. Our Smart Value Score of 34/100 indicates the stock is weak. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of -4.42, it sits in the distress. TTM revenue stands at $13.11M.
Frequently asked questions
What is Tonix Pharmaceuticals Holding Corp's stock price?
Tonix Pharmaceuticals Holding Corp (TNXP) trades at $12.93.
Is Tonix Pharmaceuticals Holding Corp overvalued?
Smart Value Score 34/100 (Grade F, Strong Sell).
What is the price target of Tonix Pharmaceuticals Holding Corp (TNXP)?
The analyst target price is $54.33, representing +320.2% upside from the current price of $12.93.
What is Tonix Pharmaceuticals Holding Corp's revenue?
TTM revenue is $13.11M.
Piotroski F-Score?
6/9 — moderate financial health.
Altman Z-Score?
-4.42 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio13.67x
ROE-64.50%
Beta1.76
50D MA$13.99
200D MA$22.52
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—